超稳定的胰岛素-葡萄糖融合蛋白利用内源性肝切换来减轻低血糖风险
Nicolas Varas1, Mark A Jarosinski1, Yen-Shan Chen1
1Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, 635 Barnhill Dr, Indianapolis, Indiana 46204, United States.
ACS pharmacology & translational science
|September 19, 2025
概括
一种新型的葡萄糖-胰岛素融合蛋白通过响应葡萄糖水平,为糖尿病管理提供了更简单的方法. 这种稳定的融合蛋白旨在改善血糖控制并降低低血糖的风险,可能扩大全球胰岛素的获取.
科学领域:
- 生物技术是生物技术.
- 内分泌学 在内分泌学.
- 蛋白质工程是指蛋白质工程.
背景情况:
- 糖尿病胰岛素治疗受到低血糖风险的限制.
- 现有的葡萄糖反应技术包括闭环系统和智能胰岛素.
- 需要更简单,更容易获得的葡萄糖反应疗法.
研究的目的:
- 开发一种稳定的葡萄糖-胰岛素融合蛋白,利用内生葡萄糖依赖信号.
- 创建一个基底葡萄糖响应的胰岛素生物技术,增强稳定性和可访问性.
主要方法:
- 设计了一种融合蛋白与稳定葡萄糖和胰岛素部分.
- 在实验室中评估了抗纤维化和双重荷尔蒙活性的稳定性.
- 在使用连续静脉输液的老鼠中评估了葡萄糖动力学反应.
主要成果:
- 融合蛋白显示出对纤维化的耐药性和平衡的双激素信号传递.
- 在体内研究表明,在降低高血糖症方面保持有效性.
- 融合蛋白在低血糖期间增强了内源性葡萄糖的产生.
结论:
- 开发的葡萄糖-胰岛素融合蛋白为基础葡萄糖反应性胰岛素治疗提供了原则证明.
- 融合蛋白的增强稳定性可以克服冷链的局限性,改善全球访问.
- 这种方法为糖尿病管理提供了一个简单而有效的策略.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Hypoglycemia and Glucagon
838
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
838
Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K


